Quick answer: Sermorelin and CJC-1295 are both synthetic growth hormone-releasing hormone (GHRH) analogs studied in research models, differing primarily in their structure and described half-life; Sermorelin is a shorter GHRH fragment, while CJC-1295 is engineered for a longer-acting profile.
This article provides a clear, research-focused comparison of these peptide compounds, addressing common questions about sermorelin vs cjc-1295 in growth hormone research.
This comparison focuses on the class, structure, and sourcing considerations for Sermorelin and CJC-1295 in research settings.
Sermorelin and CJC-1295: Analogs of Growth Hormone-Releasing Hormone
Both compounds are synthetic analogs of growth hormone-releasing hormone (GHRH). [1] In peptide research, both are described in the literature as GHRH analogs studied for their effect on growth hormone release in research models. [3]
Sermorelin is a shorter GHRH fragment analog. [2] CJC-1295 is engineered as a long-acting GHRH analog, studied in the literature for a much longer half-life than natural GHRH. Thus, while belonging to the same class, they differ in their described persistence in research settings.
Sermorelin vs CJC-1295 at a glance
| Sermorelin | CJC-1295 | |
|---|---|---|
| Type | Injectable GHRH analog | Injectable GHRH analog |
| Research class | Growth hormone releasing hormone analog | Growth hormone releasing hormone analog |
| Structure | Shorter GHRH fragment analog | Long-acting GHRH analog |
| Documentation to demand | Per-batch COA, HPLC, mass spec | Per-batch COA, HPLC, mass spec |
None of that speaks to what either compound does in a person. The framing here is research-use-only, drawn from how the compounds are described in laboratory and animal models, not confirmed in humans.
Where each one sits in the literature
CJC-1295 is studied for its long-acting profile within the GHRH family. For a closer look at that compound on its own, see our what is CJC-1295 overview.
Sermorelin is often studied next to other GHRH analogs, and one common pairing is against tesamorelin. Our tesamorelin vs sermorelin breakdown covers that comparison and puts sermorelin in context within its class.
Sourcing Sermorelin and CJC-1295 for Research
Sourcing high-quality Sermorelin and CJC-1295 is critical for reliable research. Both compounds are popular, which can lead to variability in product quality among vendors. Researchers should prioritize vendors who provide comprehensive third-party testing documentation.
For each compound, demand a per-batch Certificate of Analysis (COA) that can be reviewed before purchase, High-Performance Liquid Chromatography (HPLC) verified purity of 99% or higher on the specific lot, mass spectrometry confirmation, and a lot number tied to your vial. These documents ensure that the compound is indeed what it is purported to be and free from significant impurities, which is paramount for drawing accurate conclusions about the peptide's effects. For guidance on verifying vendor claims, see our guide on How to Verify a Research Peptide Vendor in 2026.
Peptide Hackers carries both Sermorelin and CJC-1295 with this documentation on every batch, third-party tested through Janoshik. A live Certificate of Analysis can be viewed before ordering, with options for same-day pickup in Los Angeles or Newport Beach, or shipping.
All products are for laboratory research only. Not for human or veterinary use.
Frequently Asked Questions
What are Sermorelin and CJC-1295?
Both Sermorelin and CJC-1295 are synthetic analogs of growth hormone-releasing hormone (GHRH) studied in research models. They are investigated for their potential effects on growth hormone release in laboratory settings.
How do Sermorelin and CJC-1295 differ in research applications?
While both are GHRH analogs, their primary difference lies in their structure and described half-life. Sermorelin is a shorter GHRH fragment analog, typically studied for a shorter duration of action. CJC-1295 is engineered as a long-acting GHRH analog, designed for a much longer half-life in research models. For more details on CJC-1295, see our overview: What Is CJC-1295?.
Why is third-party testing important when sourcing Sermorelin and CJC-1295 for research?
Third-party testing, including a Certificate of Analysis (COA), HPLC verified purity, and mass spectrometry confirmation, is crucial to ensure the quality and purity of research peptides. Contaminated or impure compounds can lead to unreliable experimental results. Researchers should demand this documentation to verify the identity and purity of their materials. Learn more about verifying vendor claims in our guide: How to Verify a Research Peptide Vendor in 2026.
Are Sermorelin and CJC-1295 intended for human use?
No. Consistent with the research-use-only framing of this site, Sermorelin and CJC-1295 are strictly for laboratory research purposes. They are not approved for human or veterinary use.
References
- Advances in the detection of growth hormone releasing hormone synthetic analogs — Drug Test Anal (2021). PMID: 34665524
- A potentially effective drug for patients with recurrent glioma: sermorelin — Ann Transl Med (2021). PMID: 33842627
- Mesenchymal Stem cell therapy with GHRH receptor analog resolves post-stroke vasogenic edema via modulating AQP4 and mitochondria-ER crosstalk — J Transl Med (2026). PMID: 42063069
Research Use Only
This article is provided for educational purposes. All peptides discussed are sold for research use only and are not intended for human consumption or therapeutic use.